Effectiveness of Prism Spectacles in Patients With Age Related Macular Degeneration
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Age-Related Macular Degeneration
- Sponsor
- University of Faisalabad
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Visual Acuity
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
A study is conducted to determine the effectiveness of prism spectacles in improving visual acuity with age related macular degeneration patients and to assess the improvement in quality of life in patients by using prism spectacles.
Detailed Description
A random sampling technique will be used to allocate patient in interventional and non-interventional group. The diagnosed patients of age-related macular degeneration are assessed for prism spectacles for near vision and prism glasses will be dispensed to the patients. Each subject will be interviewed to fill the Proforma after taking the informed consent. The results of this study will show the effectiveness of prism glasses in patients with age related macular degeneration in their daily routine near work as compared to conventional glasses.
Investigators
mehreen tanveer
principal investigator
University of Faisalabad
Eligibility Criteria
Inclusion Criteria
- •Patients having age \>50 years with age related macular degeneration.
- •Patients of both genders (male and female).
- •Participants who will be willing to give informed consent for participation in the study.
Exclusion Criteria
- •Presence of all ocular disease and systemic ocular pathologies able to impair visual function.
- •Presence of disorders causing choroidal neovascularization other than age related macular degeneration.
- •Patients with mental illness, dementia, and severe physical limitations
Outcomes
Primary Outcomes
Visual Acuity
Time Frame: Four week
Near and Distance visual acuity are measured in log Mar units.
Visual Functional Quality of life (VFQOL)
Time Frame: Four weeks
VFQOL is measured by a validated tool VFQOL-25.